Eric Lawitz Selected Research

ruzasvir

1/2019	Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection.
1/2019	Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.
11/2017	Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eric Lawitz Research Topics

Disease

75	Infections 01/2021 - 11/2007
44	Fibrosis (Cirrhosis) 01/2022 - 08/2012
39	Chronic Hepatitis C 01/2019 - 11/2007
17	Hepatitis C 06/2019 - 08/2008
14	Fatigue 05/2019 - 04/2013
11	Anemia 01/2017 - 10/2010
9	Non-alcoholic Fatty Liver Disease 11/2020 - 01/2018
9	Nausea 01/2017 - 04/2013
8	Liver Diseases (Liver Disease) 01/2021 - 02/2014
8	Headache (Headaches) 05/2019 - 04/2012
6	Diarrhea 05/2019 - 04/2012
5	Alcoholic Fatty Liver 01/2022 - 10/2018
5	Chronic Renal Insufficiency 01/2022 - 06/2016
5	Virus Diseases (Viral Diseases) 01/2018 - 08/2012
4	Pruritus (Itching) 01/2022 - 08/2008
4	Persistent Infection 01/2015 - 11/2007
4	Neutropenia 06/2013 - 06/2011
3	Chronic Kidney Failure (Chronic Renal Failure) 01/2022 - 07/2014
3	Inflammation (Inflammations) 01/2020 - 08/2012
3	Sleep Initiation and Maintenance Disorders (Insomnia) 05/2019 - 05/2013
2	Mental Disorders (Mental Disorder) 01/2021 - 02/2014
2	Portal Hypertension 06/2020 - 01/2020
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2018 - 01/2018
2	Chronic Disease (Chronic Diseases) 08/2014 - 06/2014
2	Exanthema (Rash) 07/2013 - 08/2008
1	Cardiovascular Diseases (Cardiovascular Disease) 10/2020
1	Hypertriglyceridemia 02/2020
1	Cicatrix (Scar) 01/2020
1	Hepatic Encephalopathy 01/2020
1	Overweight 10/2019
1	End Stage Liver Disease 05/2019
1	Kidney Diseases (Kidney Disease) 02/2019
1	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 01/2019

Drug/Important Bio-Agent (IBA)

62	Ribavirin (Virazole)FDA LinkGeneric 10/2020 - 08/2008
32	SofosbuvirIBA 01/2022 - 01/2013
29	Antiviral Agents (Antivirals)IBA 01/2021 - 11/2007
28	InterferonsIBA 01/2019 - 12/2009
22	Protease Inhibitors (Protease Inhibitor)IBA 01/2018 - 04/2012
13	NucleotidesIBA 01/2019 - 03/2013
10	Pharmaceutical PreparationsIBA 01/2022 - 06/2013
9	daclatasvirIBA 06/2020 - 12/2011
8	RNA (Ribonucleic Acid)IBA 05/2019 - 12/2011
8	paritaprevirIBA 05/2019 - 01/2013
8	peginterferon alfa-2a (Pegasys)FDA Link 02/2015 - 08/2008
7	ledipasvirIBA 10/2020 - 02/2014
7	Ritonavir (Norvir)FDA Link 05/2019 - 01/2013
7	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 09/2015 - 03/2011
6	Biomarkers (Surrogate Marker)IBA 11/2020 - 01/2018
6	SimeprevirIBA 06/2020 - 06/2014
6	ombitasvirIBA 05/2019 - 01/2014
6	Proteins (Proteins, Gene)FDA Link 01/2019 - 07/2014
6	grazoprevirIBA 11/2017 - 03/2015
5	glecaprevir and pibrentasvirIBA 01/2021 - 10/2017
5	dasabuvirIBA 05/2019 - 01/2013
5	velpatasvirIBA 11/2018 - 12/2015
5	sofosbuvir drug combination ledipasvirIBA 01/2017 - 02/2014
5	elbasvirIBA 01/2017 - 03/2015
5	telaprevirIBA 09/2015 - 08/2008
4	8- cyclohexyl- N- ((dimethylamino)sulfonyl)- 1,1a,2,12b- tetrahydro- 11- methoxy- 1a- ((3- methyl- 3,8- diazabicyclo(3.2.1)oct- 8- yl)carbonyl)cycloprop(d)indolo(2,1- a)(2)benzazepine- 5- carboxamideIBA 02/2016 - 02/2014
4	asunaprevirIBA 02/2016 - 04/2012
3	Alanine Transaminase (SGPT)IBA 10/2019 - 08/2012
3	uprifosbuvirIBA 01/2019 - 11/2017
3	ruzasvirIBA 01/2019 - 11/2017
3	TabletsIBA 01/2017 - 04/2014
3	Erythropoietin FDA Link 06/2016 - 03/2011
3	vaniprevirIBA 06/2014 - 07/2013
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 11/2020 - 10/2019
2	Triglycerides (Triacylglycerol)IBA 02/2020 - 10/2019
2	Drug CombinationsIBA 01/2019 - 01/2011
2	selonsertibIBA 10/2018 - 01/2018
2	simtuzumabIBA 10/2018 - 01/2018
2	pibrentasvirIBA 01/2018 - 10/2017
2	CollagenIBA 01/2018 - 01/2018
2	wisteria lectinIBA 01/2018 - 01/2018
2	glecaprevirIBA 01/2018 - 10/2017
2	sofosbuvir velpatasvir voxilaprevir drug combinationIBA 01/2017 - 01/2017
2	voxilaprevirIBA 01/2017 - 11/2016
2	GS-9451IBA 01/2016 - 07/2014
2	NucleosidesIBA 07/2014 - 02/2014
2	peginterferon alfa-2b (Pegintron)FDA Link 01/2013 - 01/2010
1	EDP-305IBA 01/2022
1	OligonucleotidesIBA 01/2021
1	CreatinineIBA 10/2020
1	Fish OilsIBA 02/2020
1	Fatty Acids (Saturated Fatty Acids)IBA 02/2020
1	Acetyl-CoA CarboxylaseIBA 02/2020
1	Fibric Acids (Fibrates)IBA 02/2020
1	firsocostatIBA 02/2020
1	3- (2- (2- tert- butylphenylaminooxalyl)aminopropionylamino)- 4- oxo- 5- (2,3,5,6- tetrafluorophenoxy)pentanoic acidIBA 01/2020
1	AmmoniaIBA 01/2020
1	CaspasesIBA 01/2020
1	obeticholic acidIBA 12/2019
1	Insulin (Novolin)FDA Link 07/2018

Therapy/Procedure

30	Therapeutics 01/2021 - 03/2011
6	Duration of Therapy 01/2021 - 02/2015
4	Aftercare (After-Treatment) 10/2018 - 04/2014
3	Liver Transplantation 05/2019 - 01/2017
3	Retreatment 01/2017 - 03/2011
2	Contraindications 11/2015 - 02/2014
2	Drug Tapering 11/2013 - 10/2010